1. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Issue 1 (December 2016) Authors: Vandenberghe, Rik; Rinne, Juha; Boada, Mercè; Katayama, Sadao; Scheltens, Philip; Vellas, Bruno; Tuchman, Michael; Gass, Achim; Fiebach, Jochen; Hill, Derek; Lobello, Kasia; Li, David; McRae, Tom; Lucas, Prisca; Evans, Iona; Booth, Kevin; Luscan, Gerald; Wyman, Bradley; Hua, Lisa; Yang, Lingfeng Journal: Alzheimer's research & therapy Issue: Volume 8:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Issue 1 (December 2016) Authors: Ivanoiu, Adrian; Pariente, Jérémie; Booth, Kevin; Lobello, Kasia; Luscan, Gerald; Hua, Lisa; Lucas, Prisca; Styren, Scot; Yang, Lingfeng; Li, David; Black, Ronald; Brashear, H.; McRae, Thomas Journal: Alzheimer's research & therapy Issue: Volume 8:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗